Theravance Biopharma Inc (TBPH NASDAQ) stock market data APIs
$18.5457
-0.3(-1.6%)
as of November 18, 2025
Try our APIs with
free plan!
Theravance Biopharma Inc Financial Data Overview
Price chart is built with
Anychart
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Prev. Close
18.5457
Open
18.2439
High
18.5882
Low
17.8181
52 wk Range
7.9-18.96
Market Cap
914 M
P/E Ratio
31.6491
Shares Outstanding
50 672 K
Revenue
80 327 K
EPS
0.0435
Beta
0.178
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Theravance Biopharma Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Theravance Biopharma Inc data using free add-ons & libraries
Get Theravance Biopharma Inc Fundamental Data
Theravance Biopharma Inc Fundamental data includes:
- Net Revenue: 80 327 K
- EBITDA: -31 164 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-10
- EPS/Forecast: -0.1335
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Theravance Biopharma Inc News
New
Here's Why Shares in Theravance Biopharma Exploded Today
Key Points Yupelri's strength helped Theravance achieve non-GAAP profitability this quarter. The company is on track for lucrative milestones. The results of a phase 3 trial are expected in early 202...
Theravance's Q3 Earnings Surpass Estimates, Revenues Match
Theravance Biopharma TBPH reported third-quarter 2025 adjusted earnings of 4 cents per share against the Zacks Consensus Estimate of a loss of 3 cents. In the year-ago quarter, the company had incurre...
Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
YUPELRI® net sales reached an all-time high of $71.4 million, recognized by Viatris, up 15% year-over-year 1, and achieved record brand profitability Open-label portion of the pivotal Phase 3 CYPRESS...
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?
In the competitive world of small-cap biotechnology, CorMedix CRMD and Theravance Biopharma TBPH stand out as two companies working to turn scientific progress into lasting profits. Both companies, ha...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
